Imatinib plasma levels: correlation with clinical benefit in GIST patients

被引：36

作者：

Widmer, N. ^{[1
,2
]}

Decosterd, L. A. ^{[1
,2
]}

Csajka, C. ^{[1
,2
]}

Montemurro, M. ^{[3
]}

Haouala, A. ^{[1
,2
]}

Leyvraz, S. ^{[3
]}

Buclin, T. ^{[1
,2
]}

机构：

[1] CHU Vaudois, Div Clin Pharmacol & Toxicol, CH-1011 Lausanne, Switzerland

[2] Univ Lausanne, Hop Beaumont 06 605, CH-1011 Lausanne, Switzerland

[3] CHU Vaudois, Multidisciplinary Oncol Ctr, CH-1011 Lausanne, Switzerland

来源：

BRITISH JOURNAL OF CANCER | 2010年 / 102卷 / 07期

关键词：

GASTROINTESTINAL STROMAL TUMORS; CHRONIC MYELOID-LEUKEMIA; PHARMACOKINETICS;

D O I：

10.1038/sj.bjc.6605584

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1198 / 1199

页数：2

共 10 条

[1] Therapeutic drug monitoring in CML patients on imatinib [J].

Blasdel, Carolyn ;

Egorin, Merrill J. ;

Lagattuta, Theodore F. ;

Druker, Brian J. ;

Deininger, Michael W. .

BLOOD, 2007, 110 (05) :1699-1701

[2] Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors [J].

Delbaldo, Catherine ;

Chatelut, Etienne ;

Re, Micheline ;

Deroussent, Alain ;

Seronie-Vivien, Sophie ;

Jambu, Aurore ;

Berthaud, Patrice ;

Le Cesne, Axel ;

Blay, Jean-Yves ;

Vassal, Gilles .

CLINICAL CANCER RESEARCH, 2006, 12 (20) :6073-6078

[3] Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors [J].

Demetri, George D. ;

Wang, Yanfeng ;

Wehrle, Elisabeth ;

Racine, Amy ;

Nikolova, Zariana ;

Blanke, Charles D. ;

Joensuu, Heikki ;

von Mehren, Margaret .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3141-3147

[4] Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry [J].

Haouala, A. ;

Zanolari, B. ;

Rochat, B. ;

Montemurro, M. ;

Zaman, K. ;

Duchosal, M. A. ;

Ris, H. B. ;

Leyvraz, S. ;

Widmer, N. ;

Decosterd, L. A. .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2009, 877 (22) :1982-1996

[5] Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J].

Heinrich, MC ;

Corless, CL ;

Demetri, GD ;

Blanke, CD ;

von Mehren, M ;

Joensuu, H ;

McGreevey, LS ;

Chen, CJ ;

Van den Abbeele, AD ;

Druker, BJ ;

Kiese, B ;

Eisenberg, B ;

Roberts, PJ ;

Singer, S ;

Fletcher, CDM ;

Silberman, S ;

Dimitrijevic, S ;

Fletcher, JA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4342-4349

[6] Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group [J].

Judson, I ;

Ma, PM ;

Peng, B ;

Verweij, J ;

Racine, A ;

di Paola, FD ;

van Glabbeke, M ;

Dimitrijevic, S ;

Scurr, M ;

Dumez, H ;

van Oosterom, A .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (04) :379-386

[7] Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study [J].

Larson, Richard A. ;

Druker, Brian J. ;

Guilhot, Francois ;

O'Brien, Stephen G. ;

Riviere, Gilles J. ;

Krahnke, Tillmann ;

Gathmann, Insa ;

Wang, Yanfeng .

BLOOD, 2008, 111 (08) :4022-4028

[8] Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia [J].

Picard, Stephane ;

Titier, Karine ;

Etienne, Gabriel ;

Teilhet, Ernmanuelle ;

Ducint, Dominique ;

Bernard, Marie-Agnes ;

Lassalle, Regis ;

Marit, Gerald ;

Reiffers, Josy ;

Begaud, Bernard ;

Moore, Nicholas ;

Molimard, Mathieu ;

Mahon, Francois-Xavier .

BLOOD, 2007, 109 (08) :3496-3499

[9] Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability [J].

Widmer, N. ;

Decosterd, L. A. ;

Leyvraz, S. ;

Duchosal, M. A. ;

Rosselet, A. ;

Debiec-Rychter, M. ;

Csajka, C. ;

Biollaz, J. ;

Buclin, T. .

BRITISH JOURNAL OF CANCER, 2008, 98 (10) :1633-1640

[10] Population pharmacokinetics of imatinib and the role of α1-acid glycoprotein [J].

Widmer, N. ;

Decosterd, L. A. ;

Csajka, C. ;

Leyvraz, S. ;

Duchosal, M. A. ;

Rosselet, A. ;

Rochat, B. ;

Eap, C. B. ;

Henry, H. ;

Biollaz, J. ;

Buclin, T. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (01) :97-112

← 1 →